
Photo from Sharlene Gill/LinkedIn
Jan 29, 2025, 07:39
Sharlene Gill: Practice-changing ALASCCA ph3 trial
Sharlene Gill, Medical Oncologist and Medical Director, Staff Wellness and Engagement at BC Cancer, shared a post on X:
“Practice-changing ALASCCA ph3 trial
ASA 160mg in PIK3CA+ stage II-III CRC
PIK3CA+ in 37%
HR 0.42 for 3yr DFS!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 17, 2025, 07:42
Aug 17, 2025, 07:15
Aug 17, 2025, 07:09
Aug 17, 2025, 06:59
Aug 17, 2025, 06:50
Aug 17, 2025, 06:39
Aug 17, 2025, 06:11